J. Perz, G. Armstrong, L. Farrington, Y. Hutin, and B. Bell, The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide, Journal of Hepatology, vol.45, issue.4, pp.529-567, 2006.
DOI : 10.1016/j.jhep.2006.05.013

J. Yu, Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

S. Hadziyannis, H. Sette, J. Morgan, T. Balan, V. Diago et al., Peginterferon-??2a and Ribavirin Combination Therapy in Chronic Hepatitis C, Annals of Internal Medicine, vol.140, issue.5, pp.346-55, 2004.
DOI : 10.7326/0003-4819-140-5-200403020-00010

M. Manns, J. Mchutchison, S. Gordon, V. Rustgi, M. Shiffman et al., Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial, The Lancet, vol.358, issue.9286, pp.958-65, 2001.
DOI : 10.1016/S0140-6736(01)06102-5

D. Ge, J. Fellay, A. Thompson, J. Simon, K. Shianna et al., Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance, Nature, vol.18, issue.7262, pp.399-401, 2009.
DOI : 10.1038/nature08309

Y. Tanaka, N. Nishida, M. Sugiyama, M. Kurosaki, K. Matsuura et al., Genome-wide association of IL28B with response to pegylated interferon-?? and ribavirin therapy for chronic hepatitis C, Nature Genetics, vol.131, issue.10, pp.1105-1114, 2009.
DOI : 10.1038/ng.449

C. Hezode, N. Forestier, G. Dusheiko, P. Ferenci, S. Pol et al., Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection, New England Journal of Medicine, vol.360, issue.18, pp.1839-50, 2009.
DOI : 10.1056/NEJMoa0807650

URL : https://hal.archives-ouvertes.fr/inserm-00385235

P. Kwo, E. Lawitz, J. Mccone, E. Schiff, J. Vierling et al., Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial, The Lancet, vol.376, issue.9742, pp.705-721, 2010.
DOI : 10.1016/S0140-6736(10)60934-8

J. Mchutchison, G. Everson, S. Gordon, I. Jacobson, M. Sulkowski et al., Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection, New England Journal of Medicine, vol.360, issue.18, pp.1827-1865, 2009.
DOI : 10.1056/NEJMoa0806104

J. Mchutchison, M. Manns, A. Muir, N. Terrault, I. Jacobson et al., Telaprevir for Previously Treated Chronic HCV Infection, New England Journal of Medicine, vol.362, issue.14, pp.1292-303, 2010.
DOI : 10.1056/NEJMoa0908014

T. Berg, J. Mchutchison, N. Adda, F. Poordad, M. Shiffman et al., 4 SVR WITH TELAPREVIR, PEGINTERFERON ALFA-2A AND RIBAVIRIN IN HCV PATIENTS WITH WELL-CHARACTERIZED PRIOR NULL RESPONSE, PARTIAL RESPONSE, VIRAL BREAKTHROUGH OR RELAPSE AFTER PR, Journal of Hepatology, vol.52, p.2, 2010.
DOI : 10.1016/S0168-8278(10)60006-2

I. Jacobson, J. Mchutchison, G. Dusheiko, D. Bisceglie, A. Reddy et al., Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naive patients: final results of Phase 3 ADVANCE study HCV RESPOND-2 final results: high sustained virologic response among genotype 1 previous nonresponders and relapsers to peginterferon/ribavirin when retreated with boceprevir plus PegIntron (peginterferon alfa-2b)/ribavirin, Hepatology Hepatology, vol.5252, pp.427-442, 2010.

J. Bronowicki and . Boceprevir, BOC) combined with peginterferon alfa-2b/ribavirin (P/R) for treatment-naive patients with hepatitis C virus (HCV) genotype 1: SPRINT-2 final results, Hepatology, vol.52, p.402, 2010.

K. Sherman, S. Flamm, N. Afdhal, D. Nelson, M. Sulkowski et al., Telaprevir in combination with peginterferon alfa2a and ribavirin for 24 or 48 weeks in treatment-naive genotype 1 HCV patients who achieved an extended rapid viral response: final results of Phase 3 ILLUMINATE study, Hepatology, vol.52, p.401, 2010.

J. Pawlotsky, Z. Kutalik, P. Descombes, T. Cai, D. Iulio et al., Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study, Hepatology Gastroenterology, vol.138, pp.1338-1383, 2010.

J. Mccarthy, J. Li, A. Thompson, S. Suchindran, X. Lao et al., Replicated Association Between an IL28B Gene Variant and a Sustained Response to Pegylated Interferon and Ribavirin, Gastroenterology, vol.138, issue.7, pp.2307-2321, 2010.
DOI : 10.1053/j.gastro.2010.02.009

S. Chevaliez, M. Bouvier-alias, R. Brillet, and J. Pawlotsky, Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method, Hepatology, vol.44, issue.1, pp.22-31, 2007.
DOI : 10.1002/hep.21656

M. Swain, M. Lai, M. Shiffman, W. Cooksley, S. Zeuzem et al., A Sustained Virologic Response Is Durable in Patients With Chronic Hepatitis C Treated With Peginterferon Alfa-2a and Ribavirin, Gastroenterology, vol.139, issue.5, pp.1593-601, 2010.
DOI : 10.1053/j.gastro.2010.07.009

F. Lotrich, J. Loftis, R. Ferrell, M. Rabinovitz, and P. Hauser, IL28B polymorphism is associated with both side effects and clearance of hepatitis C during interferon-alpha therapy, J Interferon Cytokine Res, 2010.

C. Mello, K. Reddy, A. Craxi, A. Martin, G. Teuber et al., Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial, Ann Intern Med, vol.150, pp.528-568, 2009.

T. Poynard, M. Colombo, J. Bruix, E. Schiff, R. Terg et al., Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy, Gastroenterology, vol.136, issue.5, pp.1618-1646, 2009.
DOI : 10.1053/j.gastro.2009.01.039

G. Taliani, G. Gemignani, C. Ferrari, A. Aceti, D. Bartolozzi et al., Pegylated Interferon Alfa-2b Plus Ribavirin in the Retreatment of Interferon-Ribavirin Nonresponder Patients, Gastroenterology, vol.130, issue.4, pp.1098-106, 2006.
DOI : 10.1053/j.gastro.2006.02.016

A. Neumann, S. Bibert, B. Haagmans, A. Soulier, F. Negro et al., 2011 IL28B POLYMORPHISM IS SIGNIFICANTLY CORRELATED WITH IFN ANTI-VIRAL EFFECTIVENESS ALREADY ON FIRST DAY OF PEGYLATED INTERFERON-?? AND RIBAVIRIN THERAPY OF CHRONIC HCV INFECTION, Journal of Hepatology, vol.52, p.468, 2010.
DOI : 10.1016/S0168-8278(10)61202-0